<DOC>
	<DOCNO>NCT01189214</DOCNO>
	<brief_summary>Add-on memantine placebo treatment proceed double-blinded fashion 12 week adjust methadone dose . During study , investigator evaluate treatment response adverse effect multiple dimension elucidate therapeutic effect add-on memantine addictive behavior . It also explore possible advantage treatment social re-adaptation psychopathogenesis opioid dependence .</brief_summary>
	<brief_title>Psychopharmacotherapy Multiple Substances Abuse</brief_title>
	<detailed_description>Opioid dependence currently severe problem public health social security . Methadone maintenance therapy may decrease criminal rate increase quality life individual opioid dependence , high drop-out rate long-term requirement use methadone major problem methadone maintenance therapy opioid dependence . Methadone another long act opioid may cause dependence . Therefore , current effort methadone maintenance therapy limit . Memantine use recognize noncompetitive N-methyl-D-aspartate receptor antagonist . It find neuroprotective effect several neurodegenerative disease recent year . Memantine could inhibit brain inflammatory response action reuroglial cell provide neurotrophic effect . Previous study also find memantine inhibitory effect addictive behavior several substance . All demonstrated combination memantine methadone treat substance dependence pro unique advantage , may superior original treatment . The main purpose study explore neuroprotective effect memantine inhibition brain inflammatory response action reuroglial cell . Besides , evaluate therapeutic effect combination memantine methadone subject opioid combine amphetamine dependence/abuse . It also investigate multiple pathogenesis addictive behavior perspective treatment response .</detailed_description>
	<mesh_term>Substance-Related Disorders</mesh_term>
	<mesh_term>Memantine</mesh_term>
	<criteria>1 . Male female patient age ≧18 ≦65 year . 2 . A diagnosis opioid abuse/dependence accord DSMIV criterion make specialist psychiatry . 3 . A diagnosis multiple drug abuse/dependence accord DSMIV criterion make specialist psychiatry . 4 . Signed informed consent patient legal representative 5 . Patient reliable caregiver expect ensure acceptable compliance visit attendance duration study . 1 . Women childbearing potential use adequate contraception per investigator judgment willing comply contraception duration study . 2 . Females pregnant nursing . 3 . Patients diagnose mental illness accord DMSIV , except Major Depressive Disorder 4 . Patient receive dextromethorphan , selective cyclo oxygenase 2 ( Cox2 ) inhibitor , antiinflammatory medication within 1 week prior first dose doubleblind medication . 5 . Current evidence uncontrolled and/or clinically significant medical condition ( e.g. , cardiac , hepatic renal failure ) , judgment investigator , would compromise patient safety preclude study participation . 6 . History intolerance valproate memantine Cox2 inhibitor . 7 . History sensitivity reaction ( e.g. , urticaria , angioedema , bronchospasm , severe rhinitis , anaphylactic shock ) precipitate memantine . 8 . Patient receive electroconvulsive therapy ( ECT ) within 4 week prior first dose doubleblind medication . 9 . Diagnosis treatment esophageal , gastric , pyloric channel , duodenal ulceration relate complication ( bleed and/or perforation ) within 30 day prior receive first dose doubleblind medication . 10 . Inclusion another study opioid dependence study another indication psychotropic 's within last 30 day prior start study . 11 . Increase total SGOT , SGPT , BUN creatinine 3X ULN ( upper limit normal ) . 12 . History idiopathic druginduced agranulocytosis . 13 . Substancerelated disorder within 6 month prior study start , borderline personality disorder , schizophrenia , major psychiatric disorder define DSMIV criterion .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2010</verification_date>
</DOC>